共 177 条
[1]
Weycker D(2008)Cost of neutropenic complications of chemotherapy Ann Oncol 19 454-460
[2]
Malin J(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266
[3]
Edelsberg J(2006)2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187-3205
[4]
Glass A(2005)Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy Cancer 103 1916-1924
[5]
Gokhale M(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-1184
[6]
Oster G(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29-35
[7]
Kuderer NM(2002)Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer Ann Oncol 13 903-909
[8]
Dale DC(1993)Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 29A 319-324
[9]
Crawford J(1991)Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325 164-170
[10]
Cosler LE(2012)Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in cancer chemotherapy patients Am J Clin Oncol 35 267-274